Durvalumab vs Imatinib

Durvalumab vs Imatinib: Overview

This comparison examines the pharmacological differences between Durvalumab and Imatinib.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Imatinib — 18 hours.

Chemical Properties

Molecular Formula: Imatinib — C29H31N7O.

Molecular Weight: Imatinib — 493.6030 g/mol.

Type: Durvalumab — Antibody; Imatinib — Small molecule.